AJIC: American Journal of Infection Control
Volume 36, Issue 2 , Pages 104-117 , March 2008

A systematic review comparing the relative effectiveness of antimicrobial-coated catheters in intensive care units

  • Prabha Ramritu, MN

      Affiliations

    • The Centre for Healthcare Related Infection Surveillance & Prevention, Princess Alexandra Hospital, Brisbane, QLD, Australia
    • ,
  • Kate Halton, MSc

      Affiliations

    • The Centre for Healthcare Related Infection Surveillance & Prevention, Princess Alexandra Hospital, Brisbane, QLD, Australia
    • Institute of Health & Biomedical Innovation, Queensland University of Technology, Brisbane, QLD, Australia
    • Corresponding Author InformationAddress correspondence to Kate Halton, MSc, Institute of Health & Biomedical Innovation, Queensland University of Technology, Kelvin Grove, 4059, Australia.
    • ,
  • Peter Collignon, MD, FRCPA

      Affiliations

    • The Canberra Hospital, Canberra, ACT, Australia
    • ,
  • David Cook, PhD, FFICANZCA

      Affiliations

    • The Canberra Hospital, Canberra, ACT, Australia
    • ,
  • David Fraenkel, BM, BS, FRACP

      Affiliations

    • Intensive Care Unit, Princess Alexandra Hospital, Brisbane, QLD, Australia
    • ,
  • Diana Battistutta, PhD

      Affiliations

    • Institute of Health & Biomedical Innovation, Queensland University of Technology, Brisbane, QLD, Australia
    • ,
  • Michael Whitby, MD, FRCP

      Affiliations

    • The Centre for Healthcare Related Infection Surveillance & Prevention, Princess Alexandra Hospital, Brisbane, QLD, Australia
    • ,
  • Nicholas Graves, PhD

      Affiliations

    • The Centre for Healthcare Related Infection Surveillance & Prevention, Princess Alexandra Hospital, Brisbane, QLD, Australia
    • Institute of Health & Biomedical Innovation, Queensland University of Technology, Brisbane, QLD, Australia

References 

  1. Pittet D, Tarara D, Wenzel RP. Nosocomial bloodstream infection in critically ill patients: excess length of stay, extra costs and attributable mortalilty. JAMA. 1994;271:1598–1601
  2. Eggimann P, Sax H, Pittet D. Catheter-related infections. Microbes Infect. 2004;6:1033–1042
  3. Byers KE, Adal KA, Anglim AM, Farr BM. Case fatality rate for catheter-related bloodstream infections: a meta-analysis (abstract 43). 5th Annual Meeting of the Society of Healthcare Epidemiology of America. San Diego: Mt. Royal, NJ: The Society of Healthcare Epidemiology of America; 1995;16(4):23.
  4. Rosenthal VD, Guzman S, Migone O, Crnich CJ. The attributable cost, length of hospital stay, and mortality of central line-associated bloodstream infection in intensive care departments in Argentina: a prospective, matched analysis. Am J Infect Control. 2003;31:475–480
  5. NNIS . National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2004, issued October 2004. Am J Infect Control. 2004;32:470–485
  6. McLaws ML, Taylor PC. The Hospital Infection Standardized Surveillance HISS programme: analysis of a two-year pilot. J Hosp Infect. 2003;53:259–267
  7. Centers for Disease Control and Prevention . Guidelines for the prevention of intravascular catheter-related infections. MMWR. 2002;51(RR-10):1–29
  8. Pittet D, Harbarth S, Ruef C, Francioli P, Sudre P, Petignat C, et al. Prevalence and risk factors for nosocomial infections in four university hospitals in Switzerland. Infect Control Hosp Epidemiol. 1999;20:37–42
  9. Kamal GD, Pfaller MA, Rempe LE, Jebson PJR. Reduced intravascular catheter infection by antibiotic bonding: a prospective, randomized, controlled trial. JAMA. 1991;265:2364–2368
  10. Darouiche RO, Raad , Heard SO, Thornby JI, Wenker OC, Gabrielli A, et al. A comparison of two antimicrobial-impregnated central venous catheters. Catheter Study Group. N Engl J Med. 1999;340:1–8
  11. Veenstra DL, Saint S, Saha S, Lumley T, Sullivan SD. Efficacy of antiseptic-impregnated central venous catheters in preventing catheter-related bloodstream infection: a meta-analysis. JAMA. 1999;281:261–267
  12. Marin MG, Lee JC, Skurnick JH. Prevention of nosocomial bloodstream infections: effectiveness of antimicrobial-impregnated and heparin-bonded central venous catheters. Crit Care Med. 2000;28:3332–3338
  13. Mermel LA. Prevention of intravacular catheter-related infections. Ann Intern Med. 2000;132:391–402
  14. Walder B, Pittet D, Tramèr MR. Prevention of bloodstream infections with central venous catheters treated with anti-infective agents depends on catheter type and insertion time: evidence from a meta-analysis. Infect Control Hosp Epidemiol. 2002;23:748–756
  15. Geffers C, Zuschneid I, Eckmanns T, Rüden H, Gastmeier P. The relationship between methodological trial quality and the effects of impregnated central venous catheters. Intensive Care Med. 2003;29:403–409
  16. Rubinson L, Diette GB. Best practices for insertion of central venous catheters in intensive-care units to prevent catheter-related bloodstream infections. J Lab Clin Med. 2004;143:5–13
  17. The Epic Project . Developing national evidence based guidelines for preventing hospital-acquired infections associated with the use of central venous catheters. London: Department of Health; 2000;
  18. Scottish Intercollegiate Guidelines Network. Sign 50: a guideline developer's handbook. Edinburgh, UK; 2001.
  19. Bach A, Eberhardt H, Frick A, Schmidt H, Böttiger BW, Martin E. Efficacy of silver-coating central venous catheters in reducing bacterial colonization. Crit Care Med. 1999;27:515–521
  20. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177–188
  21. Petitti DB. Meta-analysis, decision analysis and cost-effectiveness analysis. 2nd ed.. New York: Oxford University Press; 2000;
  22. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629–634
  23. Fraenkel DJ, Rickard C, Thomas P, Faoagali J, George N, Ware R. A prospective, randomized trial of rifampicin-minocycline-coated and silver-platinum-carbon impregnated central venous catheters. Crit Care Med. 2006;34:668–675
  24. Pemberton LB, Ross V, Cuddy P, Kremer H, Fessler T, McGurk E. No difference in catheter sepsis between standard and antiseptic central venous catheters: a prospective randomized trial. Arch Surg. 1996;131:986–989
  25. Marik PE, Abraham G, Careau P, Varon J, Fromm RE. The ex vivo antimicrobial activity and colonization rate of two antimicrobial-bonded central venous catheters. Crit Care Med. 1999;27:1128–1131
  26. Dunser MW, Mayr AJ, Hinterberger G, Florl CL, Ulmer H, Schmid S, et al. Central venous catheter colonization in critically ill patients: a prospective, randomized, controlled study comparing standard with two antiseptic-impregnated catheters. Anesth Analg. 2005;101:1778–1784
  27. Hannan M, Juste RN, Umasanker S, Glendenning A, Nightingale C, Azadian B, et al. Antiseptic-bonded central venous catheters and bacterial colonisation. Anaesthesia. 1999;54:868–872
  28. van Vliet J, Leusink J. A comparison between two types of central venous catheters in the prevention of catheter related infections: the importance of performing all the relevant cultures. Clin Intensive Care. 2001;12:135–140
  29. Hanley EM, Veeder A, Smith T, Drusano G, Currie E, Venezia RA. Evaluation of an antiseptic triple-lumen catheter in an intensive care unit. Crit Care Med. 2000;28:366–370
  30. Thornton J, Todd NJ, Webster NR. Central venous line sepsis in the intensive care unit. Anaesthesia. 1996;51:1018–1020
  31. Civetta JM, Hudson-Civetta J, Ball S. Decreasing catheter-related infection and hospital costs by continuous quality improvement. Crit Care Med. 1996;24:1660–1665
  32. Bach A, Schmidt H, Böttiger B, Schreiber B, Böhrer H, Motsch J, et al. Retention of antibacterial activity and bacterial colonization of antiseptic-bonded central venous catheters. J Antimicrob Chemother. 1996;37:315–322
  33. George SJ, Vuddamalay P, Boscoe MJ. Antiseptic-impregnated central venous catheters reduce the incidence of bacterial colonization and associated infection in immunocompromised transplant patients. Eur J Anaesth. 1997;14:428–431
  34. Loo S, van Heerden PV, Gollege CL, Roberts BL, Power BM. Infection in central lines: antiseptic-impregnated vs standard non-impregnated catheters. Anaesth Intensive Care. 1997;25:637–639
  35. Maki DG, Stolz SM, Wheeler S, Mermel LA. Prevention of central venous catheter-related bloodstream infection by use of an antiseptic-impregnated catheter: a randomized, controlled trial. Ann Intern Med. 1997;127:257–266
  36. Heard SO, Wagle M, Vijayakumar E, McLean S, Brueggemann A, Napolitano LM, et al. Influence of triple-lumen central venous catheters coated with chlorhexidine and silver sulfadiazine on the incidence of catheter-related bacteremia. Arch Intern Med. 1998;158:81–87
  37. Sheng WH, Ko WJ, Wang JT, Chang SC, Hsueh PR, Luh KT. Evaluation of antiseptic-impregnated central venous catheters for prevention of catheter-related infection in intensive care unit patients. Diagn Microbiol Infect Dis. 2000;38:1–5
  38. Theaker C, Juste R, Lucas N, Tallboys C, Azadian B, Soni N. Comparison of bacterial colonization rates of antiseptic impregnated and pure polymer central venous catheters in the critically ill. J Hosp Infect. 2002;52:310–312
  39. Richards B, Chaboyer W, Bladen T, Schluter PJ. Effect of central venous catheter type on infections: a prospective clinical trial. J Hosp Infect. 2003;54:10–17
  40. Brun-Buisson C, Doyon Fo, Sollet J-P, Cochard J-Fo, Cohen Y, Nitenberg Gr. Prevention of intravascular catheter-related infection with newer chlorhexidine-silver sulfadiazine-coated catheters: a randomized controlled trial. Intensive Care Med. 2004;30:837–843
  41. Rupp ME, Lisco SJ, Lipsett PA, Perl TM, Keating K, Civetta JM, et al. Effect of a second-generation venous catheter impregnated with chlorhexidine and silver sulfadiazine on central catheter-related infections: a randomised controlled trial. Ann Intern Med. 2005;143:570–580
  42. Corral L, Nolla-Salas M, Ibañez-Nolla J, León MA, Díaz RM, Martin MC, et al. A prospective, randomized study in critically ill patients using the OLIGON VANTEX catheter. J Hosp Infect. 2003;55:212–219
  43. Moretti EW, Ofstead CL, Kristy RM, Wetzler HP. Impact of central venous catheter type and methods on catheter-related colonization and bacteraemia. J Hosp Infect. 2005;61:139–145
  44. Stoiser B, Kofler J, Staudinger T, Georgopoulos A, Lugauer S, Guggenbichler JP, et al. Contamination of central venous catheters in immunocompromised patients: a comparison between two different types of central venous catheters. J Hosp Infect. 2002;50:202–261
  45. Lugauer S, Regenfus A, Böswald M, Martus P, Geis C, Bechert T, et al. Sicherung der klinischen Diagnose einer Katheter-assoziierten Infektion anhand eines Bewertungsscores. Infection. 1998;26(Suppl 1):S53–S58
  46. Lugauer S, Regenfus A, Böswald M, Martus P, Geis C, Bechert T, et al. A new scoring system for the clinical diagnosis of catheter-related infections. Infection. 1999;27:S49–S53
  47. Raad I, Darouiche R, Dupuis J, Abi-Said D, Gabrielli A, Hachem R, et al. Central venous catheters coated with minocycline and rifampin for the prevention of catheter-related colonization and bloodstream infections: a randomized, double-blind trial. The Texas Medical Center Catheter Study Group. Ann Intern Med. 1997;127:267–274
  48. Chatzinikolaou I, Finkel K, Hanna H, Boktour M, Foringer J, Ho T, et al. Antibiotic-coated hemodialysis catheters for the prevention of vascular catheter-related infections: a prospective, randomized study. Am J Med. 2003;115:352–357
  49. Leon C, Ruiz-Santana S, Rello J, de la Torre MV, Valles J, Alvarez-Lerma F, et al. Benefits of minocycline and rifampin-impregnated central venous catheters. Intensive Care Med. 2004;30:1891–1899
  50. Yucel N, Lefering R, Maegele M, Max M, Rossaint R, Koch A, et al. Reduced colonization and infection with miconazole-rifampicin modified central venous catheters: a randomized controlled clinical trial. J Antimicrob Chemother. 2004;54:1109–1115
  51. Sherertz RJ, Heard SO, Raad , Gentry L, Bowton D, Scuderi P, et al. Gamma radiation-sterilized, triple-lumen catheters coated with a low concentration of chlorhexidine were not efficacious at preventing catheter infections in intensive care unit patients. Antimicrob Agents Chemother. 1996;40:1995–1997
  52. Kamal GD, Divishek D, Kumar GC, Porter BR, Tatman DJ, Adams JR. Reduced intravascular catheter-related infection by routine use of antibiotic-bonded catheters in a surgical intensive care unit. Diagn Microbiol Infect Dis. 1998;30:145–152
  53. Appelgren P, Ransjo U, Bindslev L, Espersen F, Larm O. Surface heparinization of central venous catheters reduces microbial colonization in vitro and in vivo: results from a prospective, randomized trial. Crit Care Med. 1996;24:1482–1489
  54. Ranucci M, Isgr ÃG, Giomarelli PP, Pavesi M, Luzzani A, Cattabriga I, et al. Impact of oligon central venous catheters on catheter colonization and catheter-related bloodstream infection. Crit Care Med. 2003;31:52–59
  55. Carrasco MN, Bueno A, de las Cuevas C, Jimenez S, Salinas I, Sartorius A, et al. Evaluation of a triple-lumen central venous heparin-coated catheter versus a catheter coated with chlorhexidine and silver sulfadiazine in critically ill patients. Intensive Care Med. 2004;30:633–638
  56. McConnell SA, Gubbins PO, Anaissie EJ. Do antimicrobial-impregnated central venous catheters prevent catheter-related bloodstream infection?. Clin Infect Dis. 2003;37:65–72
  57. Bassetti S, Hu J, D'Agostino RBJ, Sherertz RJ. Prolonged antimicrobial activity of a catheter containing chlorhexidine-silver sulfadiazine extends protection against catheter infections in vivo. Antimicrob Agents Chemother. 2001;45:1535–1538
  58. Donelli G, Francolini I. Efficacy of antiadhesive, antibiotic and antiseptic coatings in preventing catheter-related infections: review. J Chemother. 2001;13:595–606
  59. Pai MP, Pendland SL, Danziger LH. Antimicrobial-coated/bonded and-impregnated intravascular catheters. Ann Pharmacother. 2001;35:1255–1263
  60. Gastmeier P, Zuschneid I, Geffers C. Antimicrobially impregnated catheters: an overview of randomised controlled trials. J Vasc Access. 2003;4:102–110
  61. Sampath LA, Tambe SM, Modak SM. In vitro and in vivo efficacy of catheters impregnated with antiseptics or antibiotics: evaluation of the risk of bacterial resistance to the antimicrobials in the catheters. Infect Control Hosp Epidemiol. 2001;22:640–646
  62. Chatzinikolaou I, Hanna H, Graviss L, Chaiban G, Perego C, Arbuckle R, et al. Clinical experience with minocycline and rifampin-impregnated central venous catheters in bone marrow transplantation recipients: efficacy and low risk of developing staphylococcal resistance. Infect Control Hosp Epidemiol. 2003;24:961–963
  63. Hanna HA, Raad , Hackett B, Wallace SK, Price KJ, Coyle DE, et al. Antibiotic-impregnated catheters associated with significant decrease in nosocomial and multidrug-resistant bacteremias in critically ill patients. Chest. 2003;124:1030–1038
  64. Sutton AJ, Duval SJ, Tweedie RL, Abrams KR, Jones DR. Empirical assessment of effect of publication bias on meta-analyses. BMJ. 2000;320:1574–1577
  65. Crnich CJ, Maki DG. Are antimicrobial-impregnated catheters effective? Don't throw out the baby with the bathwater. Clin Infect Dis. 2004;38:1287–1292
  66. McConnell SA, Gubbins PO, Anaissie EJ. Are antimicrobial-impregnated catheters effective? Replace the water and grab your washcloth, because we have a baby to wash. Clin Infect Dis. 2004;39:1829–1833
  67. Gillies D, O'Riordan E, Carr D, O'Brien L, Frost J, Gunning R. Central venous catheter dressings: a systematic review. J Adv Nurs. 2003;44:623–632
  68. Cook D, Kernerman P, Cupido C, King D, et al. Central venous catheter replacement strategies: a systematic review of the literature. Crit Care Med. 1997;25:1417–1424
  69. Hu KK, Veenstra DL, Lipsky BA, Saint S. Use of maximal sterile barriers during central venous catheter insertion: clinical and economic outcomes. Clin Infect Dis. 2004;39:1441–1445
  70. Safdar N, Maki DG. The pathogenesis of catheter-related bloodstream infection with noncuffed short-term central venous catheters. Intensive Care Med. 2004;30:62–67
  71. Rijnders BJ, Van Wijngaerden E, Peetermans WE. Catheter-tip colonization as a surrogate end point in clinical studies on catheter-related bloodstream infection: how strong is the evidence?. Clin Infect Dis. 2002;35:1053–1058
  72. Buyse M, Molenberghs G, Burzykowski T, Renard D, Geys H. The validation of surrogate endpoints in meta-analyses of randomized experiments. Biostatistics. 2000;1:49–67
  73. Rello J, Ochagavia A, Sabanes E, Roque M, Mariscal D, Reynaga E, et al. Evaluation of outcome of intravenous catheter-related infections in critically ill patients. Am J Respir Crit Care Med. 2000;162:1027–1030
  74. Lark RL, Chenoweth C, Saint S, Zemencuk JK, Lipsky BA, Plorde JJ. Four-year prospective evaluation of nosocomial bacteremia: epidemiology, microbiology and patient outcome. Diagn Microbiol Infect Dis. 2000;38:131–140
  75. Cooper BS, Stone SP, Kibbler CC, Cookson BD, Roberts JA, Medley GF, et al. Systematic review of isolation policies in the hospital management of methicillin-resistant Staphylococcus aureus: a review of the literature with epidemiological and economic modelling. Health Technol Assess. 2003;7:1–194
  76. Salgado CD, Farr BM. Outcomes associated with vancomycin-resistant enterococci: a meta-analysis. Infect Control Hosp Epidemiol. 2003;24:690–698
  77. Buxton MJ, Drummond M, van Hout BA, Prince RL, Sheldon TA, Szucs T, et al. Modelling in economic evaluation: an unavoidable fact of life. Health Econ. 1997;6:217–227
  78. Kuntz KM, Weinstein MC. Modelling in economic evaluation. In:  Drummond M,  McGuire A editor. Economic evaluation in health care. Oxford, UK: Oxford University Press; 2001;p. 141–171
  79. Halpern MT, Luce BR, Brown RE, Geneste B. Health and economic outcomes modeling practices: a suggested framework. Value Health. 1998;1:131–147
  80. Luce BR. What will it take to make cost-effectiveness analysis acceptable in the United States?. Med Care. 2005;43(Suppl 7):44–48
  81. Claxton K, Sculpher M, Drummond M. A rational framework for decision making by the National Institute for Clinical Excellence. Lancet. 2002;360:711–715
  82. George B, Harris A, Mitchell A. Cost-effectiveness analysis and the consistency of decision making: evidence from pharmaceutical reimbursement in Australia (1991 to 1996). Pharmacoeconomics. 2001;19:1103–1109
  83. Veenstra DL, Saint S, Sullivan SD. Cost-effectiveness of antiseptic-impregnated central venous catheters for the prevention of catheter-related bloodstream infection. JAMA. 1999;282:554–560
  84. Shorr AF, Humphreys CW, Helman DL. New choices for central venous catheters. Chest. 2003;124:275–284
  85. Marciante KD, Veenstra DL, Lipsky BA, Saint S. Which antimicrobial impregnated central venous catheter should we use? Modeling the costs and outcomes of antimicrobial catheter use. Am J Infect Control. 2003;31:1–8
  86. Borschel DM, Chenoweth CE, Kaufman SR, Vander Hyde K, VanDerElzen KA, Raghunathan TE, et al. Are antiseptic-coated central venous catheters effective in a real-world setting?. Am J Infect Control. 2006;34:388–393
  87. Soufir L, Timsit JF, Mahe C, Carlet J, Regnier B, Chevret S. Attributable morbidity and mortality of catheter-related septicemia in critically ill patients: a matched, risk-adjusted, cohort study. Infect Control Hosp Epidemiol. 1999;20:396–401

 Supported by The Centre for Healthcare Related Infection Surveillance and Prevention (CHRISP), Queensland Health, which provided funding to the Queensland University of Technology for the development/publication of this research, and by the National Health & Medical Research Council of Australia, which awarded a project grant for this research.

PII: S0196-6553(07)00527-5

doi: 10.1016/j.ajic.2007.02.012

AJIC: American Journal of Infection Control
Volume 36, Issue 2 , Pages 104-117 , March 2008

Article Tools

* Image Usage & Resolution